The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Haematopoetic stem cell transplantation for refractory autoimmune cytopenia

På svenska

Author

  • JR Passweg
  • M Rabusin
  • M Musso
  • Y Beguin
  • S Cesaro
  • G Ehninger
  • I Espigado
  • A Iriondo
  • L Jost
  • V Koza
  • Stig Lenhoff
  • I Lisukov
  • F Locatelli
  • A Marmont
  • P Philippe
  • C Pilatrino
  • P Quartier
  • J Stary
  • P Veys
  • J Vormoor
  • A Wahlin
  • F Zintl
  • C Bocelli-Tyndall
  • A Tyndall
  • A Gratwohl
Show all

Summary, in English

This study describes the outcome of patients receiving haematopoietic stem cell transplantation (HSCT) to treat severe refractory autoimmune cytopenia. The registry of the European Group of Blood and Marrow Transplantation holds data on 36 patients receiving 38 transplants, the first transplant was autologous for 27 and allogeneic for nine patients. Patients had autoimmune haemolytic anaemia (autologous: 5; allogeneic: 2), Evans's syndrome (autologous: 2; allogeneic: 5); immune thrombocytopenia (autologous: 12), pure red cell aplasia (autologous: 4; allogeneic: 1), pure white cell aplasia (autologous: 1; allogeneic 1), or thrombotic thrombocytopenic purpura (autologous: 3). Patients had longstanding disease having failed multiple prior treatments. Among 26 evaluable patients mobilized for autologous HSCT, three died of treatment-related causes, one died of disease progression, seven were non-responders, six patients had transient responses and nine had continuous partial or complete remission. Of the seven evaluable patients receiving allogeneic HSCT, one died of treatment-related complications, one with transient response died of progressive disease and five had a continuous response. Autologous and allogeneic HSCT may induce a response in a subset of patients with autoimmune cytopenia of long duration albeit at the price of considerable toxicity.

Publishing year

2004

Language

English

Pages

749-755

Publication/Series

British Journal of Haematology

Volume

125

Issue

6

Document type

Journal article

Publisher

Wiley-Blackwell

Topic

  • Hematology

Keywords

  • autoimmune cytopenia
  • Evans's syndrome
  • pure
  • red cell aplasia
  • allogeneic
  • autologous
  • stem cell transplantation
  • immune thrombocytopenia

Status

Published

ISBN/ISSN/Other

  • ISSN: 0007-1048